STOCK TITAN

GE HealthCare Technologies Inc. - GEHC STOCK NEWS

Welcome to our dedicated page for GE HealthCare Technologies news (Ticker: GEHC), a resource for investors and traders seeking the latest updates and insights on GE HealthCare Technologies stock.

GE HealthCare Technologies Inc. (NYSE: GEHC) is a leading global innovator in medical technology, pharmaceutical diagnostics, and digital solutions. The company operates through four main segments: Imaging, Ultrasound, Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). Of these, the Imaging segment generates the majority of the company’s revenue.

GE HealthCare is dedicated to providing transformational medical technologies and services that enhance access to quality, affordable healthcare worldwide. Through its cutting-edge products and comprehensive solutions, the company aims to improve patient outcomes and streamline healthcare delivery.

Recent achievements include advancements in artificial intelligence (AI) integration within medical imaging, which supports more accurate and efficient diagnostics. The company is also involved in numerous partnerships with healthcare providers and research institutions to drive innovation and improve global healthcare standards.

Financially, GE HealthCare has showcased robust performance, with steady revenue growth and strong market presence. The company continuously invests in R&D to maintain its edge in the competitive healthcare industry. Their suite of products includes advanced imaging machines, ultrasound devices, patient monitoring systems, and contrast media for diagnostic imaging.

As part of a highly regulated industry, GE HealthCare adheres to strict compliance standards and maintains rigorous quality controls across its operations. The company actively engages with its community, although it reserves the right to monitor and manage public interactions to uphold professional and constructive discourse.

Rhea-AI Summary

GE HealthCare has completed Phase I subject recruitment for a novel manganese-based macrocyclic MRI contrast agent. Announced at the European Congress of Radiology in Vienna, this investigational agent offers a potential alternative to traditional gadolinium-based agents, addressing concerns about gadolinium retention in the body. The clinical trial, led by Hasse K. Zaré at Oslo University Hospital, aims to assess its safety and elimination profile. Manganese, being naturally occurring in the body, ensures efficient excretion, positioning this agent as a promising addition to GE HealthCare's portfolio in precision imaging.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.92%
Tags
-
Rhea-AI Summary

GE HealthCare has granted SonoThera exclusive global commercial licensing rights for its Optison® and Sonazoid® microbubble products. These products will aid the development of SonoThera’s innovative ultrasound-guided, nonviral gene therapy platform. The technology aims to non-invasively deliver diverse nucleic acid payloads to various organs, addressing significant delivery challenges in gene therapy. SonoThera is currently in preclinical development, preparing for Phase 1 clinical trials. Terms of the licensing agreement were not disclosed, but the collaboration underscores a shared commitment to improving patient outcomes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.37%
Tags
none
-
Rhea-AI Summary

GE HealthCare (Nasdaq: GEHC) announces that President and CEO Peter Arduini, along with Vice President and CFO Helmut Zodl, will present at two investor conferences in March 2023.

  • Citi’s 2023 Healthcare Services, Medtech, Tools & HCIT Conference on March 1, 2023, at 12:30 pm ET in New York City.
  • Oppenheimer 33rd Annual Healthcare Conference on March 14, 2023, at 10:00 am ET (virtual event).

Investors can access the events live on GE HealthCare’s Investor Relations website. GE HealthCare is a leading global innovator in medical technology and digital solutions, focused on improving patient care.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.95%
Tags
conferences
Rhea-AI Summary

GE HealthCare has signed an agreement to acquire Caption Health, Inc., an AI healthcare leader focused on early disease detection via ultrasound. This acquisition, strategic for GE's $3 billion ultrasound business, introduces AI-guided imaging, making ultrasounds more accessible for healthcare professionals. The technology aims to improve heart failure detection, particularly in at-risk patients, ultimately enhancing patient outcomes and reducing hospitalization rates. The deal's financial terms are undisclosed, and GE plans to fund it using cash on hand.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.51%
Tags
-
Rhea-AI Summary

GE HealthCare reported a strong performance for 4Q 2022, with revenues of $4.9 billion, up 8% year-over-year, and 13% organic revenue growth. Net income was $554 million compared to $564 million last year, while adjusted EBIT increased to $844 million from $827 million. The net income margin declined to 11.2% from 12.3%. Despite these challenges, the company reaffirmed 2023 guidance, anticipating organic revenue growth of 5% to 7% and adjusted EPS between $3.60 to $3.75. The CEO expressed confidence in future revenue and margin growth driven by innovation and market demand.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.03%
Tags
-
Rhea-AI Summary

GE HealthCare has expanded its collaboration with Sound Technologies to distribute the Vscan Air, a portable ultrasound device for veterinary practices in the U.S. This agreement enhances access to advanced ultrasound technologies, enabling precise examinations of various animals without ionizing radiation. The Vscan Air supports both iOS and Android applications, making it versatile and user-friendly. With a proven track record, GE HealthCare has over 30,000 ultrasound systems impacting more than 50 million patients globally. This partnership aims to revolutionize veterinary care, as highlighted by key industry leaders.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.74%
Tags
none
Rhea-AI Summary

GE HealthCare (Nasdaq: GEHC) will release its fourth quarter and full year 2022 financial results on January 30, 2023, before the market opens. A conference call and webcast will follow at 8:00 a.m. Eastern Time, accessible via their Investor Relations website. The company, a leader in medical technology and digital solutions, aims to enhance patient care efficiency and effectiveness. With over 51,000 employees and an $18 billion market presence, GE HealthCare is focused on advancing personalized healthcare over its century-long history.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.22%
Tags
none
-
Rhea-AI Summary

GE HealthCare reported strong revenue growth for Q4 and full-year 2022, driven by high customer demand and improved pricing. Q4 revenue reached approximately $4.9 billion, a 7% year-over-year increase, with organic growth at 12%. Full-year 2022 revenue totaled about $18.3 billion, marking a 4% growth. For 2023, the company anticipates organic revenue growth between 5% and 7%, an Adjusted EBIT margin of 15.0% to 15.5%, and a Free cash flow conversion exceeding 85%.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.27%
Tags
none
-
Rhea-AI Summary

GE HealthCare (GEHC) has announced its acquisition of IMACTIS, a French company specializing in computed tomography (CT) interventional guidance. This move aims to enhance GE HealthCare's IMACTIS CT-Navigation system, leveraging the company’s global scale and installed base for future expansion. IMACTIS's CT-Navigation technology facilitates accurate and efficient minimally invasive procedures, improving patient outcomes. The transaction is subject to customary closing conditions and will be funded with cash on hand. Financial details remain undisclosed.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.27%
Tags
Rhea-AI Summary

GE HealthCare (Nasdaq: GEHC) has appointed Dr. Taha Kass-Hout as Chief Technology Officer to lead a new science and technology organization aimed at advancing precision care. This initiative aligns core R&D efforts and establishes a multi-year technology roadmap focused on digital innovation and clinical research strategies. GE HealthCare currently leads the industry with 42 FDA-authorized AI medical devices. The new organization will enhance innovative solutions for personalized healthcare across its business segments to improve patient outcomes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.46%
Tags
none

FAQ

What is the current stock price of GE HealthCare Technologies (GEHC)?

The current stock price of GE HealthCare Technologies (GEHC) is $79.28 as of December 23, 2024.

What is the market cap of GE HealthCare Technologies (GEHC)?

The market cap of GE HealthCare Technologies (GEHC) is approximately 35.5B.

What does GE HealthCare Technologies Inc. do?

GE HealthCare Technologies Inc. provides transformative medical technologies, pharmaceutical diagnostics, and digital solutions to improve healthcare access and quality globally.

What are the main business segments of GE HealthCare?

The main business segments are Imaging, Ultrasound, Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx).

How does GE HealthCare generate most of its revenue?

The company generates the majority of its revenue from the Imaging segment.

What recent advancements has GE HealthCare made?

GE HealthCare has made significant advancements in AI integration within medical imaging, improving diagnostic accuracy and efficiency.

Who are GE HealthCare's partners?

The company collaborates with healthcare providers and research institutions to drive innovation and improve healthcare standards.

How does GE HealthCare ensure compliance?

GE HealthCare adheres to strict regulatory compliance standards and maintains rigorous quality controls across its operations.

What products does GE HealthCare offer?

GE HealthCare offers a range of products, including imaging machines, ultrasound devices, patient monitoring systems, and diagnostic contrast media.

What is GE HealthCare's commitment to the community?

The company engages actively with its community and strives to maintain professional and positive interactions while monitoring public posts and conversations.

How has GE HealthCare performed financially?

GE HealthCare has shown robust financial performance with steady revenue growth, supported by continuous investment in research and development.

What is GE HealthCare's mission?

GE HealthCare is committed to improving patient outcomes and making quality healthcare more accessible and affordable worldwide.

GE HealthCare Technologies Inc.

Nasdaq:GEHC

GEHC Rankings

GEHC Stock Data

35.46B
442.78M
3.09%
83.53%
1.91%
Health Information Services
X-ray Apparatus & Tubes & Related Irradiation Apparatus
Link
United States of America
CHICAGO